ReviewAtherosclerosis2020
Managing hyperlipidaemia in patients with COVID-19 and during its pandemic: An expert panel position statement from HEART UK.
Review in Atherosclerosis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies.Diabetes & metabolism · 2021 · on this mapPooled it
- COVID-19 and Cardiomyopathy: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- Article
- New insights into the management of homozygous familial hypercholesterolemia patients treated with lomitapide: a single-center experience.Frontiers in endocrinology · 2024Review
- Dose Intervals and Time since Final Dose on Changes in Metabolic Indices after COVID-19 Vaccination.Vaccines · 2023Article
- Fatal rhabdomyolysis caused by COVID-19 infection: a case report.Annals of medicine and surgery (2012) · 2023Article
- Review
- Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.The lancet. Diabetes & endocrinology · 2023Article
- Retrospective cohort study to evaluate the continuous use of anticholesterolemics and diuretics in patients with COVID-19.Frontiers in medicine · 2023Article
- Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.Reviews in cardiovascular medicine · 2022Review
- Effect of Comorbidities on the Infection Rate and Severity of COVID-19: Nationwide Cohort Study With Propensity Score Matching.JMIR public health and surveillance · 2022Article
- Clinical profile of patients with type 2 diabetes after COVID-19 vaccination: A prospective study.Obesity medicine · 2022Article
- Influence of statin treatment in a cohort of patients admitted for COVID-19.Medicina clinica · 2022Observational
- Influence of statin treatment in a cohort of patients admitted for COVID-19.Medicina clinica (English ed.) · 2022Article
- Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices.Preventive medicine reports · 2022Review
- Acute Coronary Syndrome in the COVID-19 Era-Differences and Dilemmas Compared to the Pre-COVID-19 Era.Journal of clinical medicine · 2022Review
- A rare case of COVID-19 pneumonia with severe hyperlipoproteinemia.Oxford medical case reports · 2022Article
- Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review.Current cardiology reviews · 2022Review
- Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants.Research (Washington, D.C.) · 2022Article
- Pharmacotherapeutic agents for the management of COVID-19 patients with preexisting cardiovascular disease.Expert opinion on pharmacotherapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 14 institutions in 1 country.
Funding
Abstract
The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes Coronavirus Disease 2019 (COVID-19) has resulted in a pandemic. SARS-CoV-2 is highly contagious and its severity highly variable. The fatality rate is unpredictable but is amplified by several factors including advancing age, atherosclerotic cardiovascular disease, diabetes mellitus, hypertension and obesity. A large proportion of patients with these conditions are treated with lipid lowering medication and questions regarding the safety of continuing lipid-lowering medication in patients infected with COVID-19 have arisen. Some have suggested they may exacerbate their condition. It is important to consider known interactions with lipid-lowering agents and with specific therapies for COVID-19. This statement aims to collate current evidence surrounding the safety of lipid-lowering medications in patients who have COVID-19. We offer a consensus view based on current knowledge and we rated the strength and level of evidence for these recommendations. Pubmed, Google scholar and Web of Science were searched extensively for articles using search terms: SARS-CoV-2, COVID-19, coronavirus, Lipids, Statin, Fibrates, Ezetimibe, PCSK9 monoclonal antibodies, nicotinic acid, bile acid sequestrants, nutraceuticals, red yeast rice, Omega-3-Fatty acids, Lomitapide, hypercholesterolaemia, dyslipidaemia and Volanesorsen. There is no evidence currently that lipid lowering therapy is unsafe in patients with COVID-19 infection. Lipid-lowering therapy should not be interrupted because of the pandemic or in patients at increased risk of COVID-19 infection. In patients with confirmed COVID-19, care should be taken to avoid drug interactions, between lipid-lowering medications and drugs that may be used to treat COVID-19, especially in patients with abnormalities in liver function tests.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.